Overview
About ActivSignal
BlueSCAI™:
Harness the Power of Ultra-Sensitive Protein Profiling in Multiplex
Unlock Critical Protein Biomarkers with Unprecedented Detection and Quantitation with Best-In-Class Platform.
Down to attomolar sensitivity
Ultra-sensitive for detecting the lowest abundance biomarkers.
5 Logs LOD Advantage
Up to 5 logs LOD advantage over leading multiplex proteomics platforms, head-to-head comparison.
BlueSCAI Background Removal
Detects down to <1,000 molecules per target per well, using the same antibody pairs as commercial ELISAs.
Locked-in Specificity
Paired-antibody proximity detection with NGS read-out of ligated DNA barcodes ensures high specificity.
Mechanistic Biology
Biologic perturbation mapping. Map time-resolved pathway responses to stimuli, drugs, and stressors—at high plex, from tiny samples.
Broad Dynamic Range
Measure changes across the biological spectrum. Tunable for optimal NGS read-out.
Multiplex Biomarker Quantification
ActivSignal's BlueSCAI is built on our patented Multiplex Paired-Antibody Amplified Detection (MPAD) technology — a highly specific and sensitive platform for profiling proteins and their modifications in multiplex.
BlueSCAI (Background lowering using Serial Capture, Adapter Insertion) detects protein targets using specific, dual-binding of antibody-pairs, an architecture that increases specificity, an integrated capture-release-recapture mechanism that dramatically lowers background, signal amplification, and specific NGS read-out — with a large and tunable dynamic range.
Highly scalable — from single to tens to hundreds of biomarkers, measured in multiplex from the same small sample with high specificity and sensitivity.
Earlier Detection of Pancreatic Cancer
The PanDx™ assay read-out from the patient sample, across the multiple proteins and other biomarkers in the Panel, provides a "bio-signature" for that individual.
for the detection of early-stage cancer.
Visit our website for more details.
Harness the Power of Ultra-Sensitive Protein Profiling in Multiplex
Unlock Critical Protein Biomarkers with Unprecedented Detection and Quantitation with Best-In-Class Platform.
Down to attomolar sensitivity
Ultra-sensitive for detecting the lowest abundance biomarkers.
5 Logs LOD Advantage
Up to 5 logs LOD advantage over leading multiplex proteomics platforms, head-to-head comparison.
BlueSCAI Background Removal
Detects down to <1,000 molecules per target per well, using the same antibody pairs as commercial ELISAs.
Locked-in Specificity
Paired-antibody proximity detection with NGS read-out of ligated DNA barcodes ensures high specificity.
Mechanistic Biology
Biologic perturbation mapping. Map time-resolved pathway responses to stimuli, drugs, and stressors—at high plex, from tiny samples.
Broad Dynamic Range
Measure changes across the biological spectrum. Tunable for optimal NGS read-out.
Multiplex Biomarker Quantification
ActivSignal's BlueSCAI is built on our patented Multiplex Paired-Antibody Amplified Detection (MPAD) technology — a highly specific and sensitive platform for profiling proteins and their modifications in multiplex.
BlueSCAI (Background lowering using Serial Capture, Adapter Insertion) detects protein targets using specific, dual-binding of antibody-pairs, an architecture that increases specificity, an integrated capture-release-recapture mechanism that dramatically lowers background, signal amplification, and specific NGS read-out — with a large and tunable dynamic range.
Highly scalable — from single to tens to hundreds of biomarkers, measured in multiplex from the same small sample with high specificity and sensitivity.
Earlier Detection of Pancreatic Cancer
The PanDx™ assay read-out from the patient sample, across the multiple proteins and other biomarkers in the Panel, provides a "bio-signature" for that individual.
for the detection of early-stage cancer.
Visit our website for more details.